Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia:
ELN
and Mayo Genetic Risk–Stratified Analysis in 540 Patients
Study limitation reported by the research below: “Single-center retrospective design at Mayo Clinic limits generalizability to other practice settings and patient populations.”